Inventor · disambiguated record
Curran Matthew Simpson
Also filed as: SIMPSON CURRAN · SIMPSON CURRAN M · SIMPSON CURRAN MATTHEW
6 granted patents·10 pending applications·386 citations·filing 1987–2025
85Inventor score
Top patents by PatentIndex Score
16 records- 0192US5324649AEnzyme-containing granules coated with hydrolyzed polyvinyl alcohol or copolymer thereofGENENCOR INT·Filed 1992·Granted Jun 28, 1994·318 cites·38 claims
- 0284US6316240B1Recovery of a glycosidase or peptidase from a culture broth at high pHNOVOZYMES AS·Filed 2000·Granted Nov 13, 2001·24 cites·11 claims
- 0372US2024254214A1TREATMENT OF OCULAR DISEASES WITH FULLY-HUMAN POST-TRANSLATIONALLY MODIFIED ANTI-VEGF FabREGENXBIO INC·Filed 2023·Application pending·0 cites
- 0471US11613739B2Treatment of mucopolysaccharidosis II with recombinant human iduronate-2-sulfatase (IDS) produced by human neural or glial cellsREGENXBIO INC·Filed 2018·Granted Mar 28, 2023·1 cites·16 claims
- 0567US2025051740A1Treatment of mucopolysaccharidosis ii with recombinant human iduronate-2-sulfatase (ids) produced by human neural or glial cellsREGENXBIO INC·Filed 2024·Application pending·0 cites
- 0666US2023057519A1Treatment of Ocular Diseases with Fully-Human Post-Translationally Modified Anti-VEGF FabREGENXBIO INC·Filed 2022·Application pending·0 cites
- 0764US6031082AIncreased yields of a crystallized protein by using a solid adsorption materialNOVO NORDISK AS·Filed 1998·Granted Feb 29, 2000·25 cites·17 claims
- 0864US2025320287A1TREATMENT OF OCULAR DISEASES WITH FULLY-HUMAN POST-TRANSLATIONALLY MODIFIED ANTI-VEGF FabREGENXBIO INC·Filed 2025·Application pending·0 cites
- 0963US2024050537A1Treatment of mucopolysaccharidosis i with fully-human glycosylated human alpha-l-iduronidase (idua)REGENXBIO INC·Filed 2023·Application pending·0 cites
- 1060US4806665APreparation of silica solNALCO CHEMICAL CO·Filed 1987·Granted Feb 21, 1989·13 cites·7 claims
- 1156US2019211091A1Treatment of Ocular Diseases with Fully-Human Post-Translationally Modified Anti-VEGF FabREGENXBIO INC·Filed 2019·Application pending·0 cites
- 1255US2020277364A1TREATMENT OF OCULAR DISEASES WITH FULLY-HUMAN POST-TRANSLATIONALLY MODIFIED ANTI-VEGF FabREGENXBIO INC·Filed 2018·Application pending·0 cites
- 1350US2019127455A1Treatment of Ocular Diseases with Fully- Human Post-Translationally Modified Anti-VEGF FabREGENXBIO INC·Filed 2017·Application pending·0 cites
- 1447US2019358303A1Treatment of mucopolysaccharidosis i with fully-human glycosylated human alpha-l-iduronidase (idua)REGENXBIO INC·Filed 2018·Application pending·0 cites
- 1540US2021275647A1Treatment of mucopolysaccharidosis i with fully-human glycosylated human alpha-l-iduronidase (idua)REGENXBIO INC·Filed 2019·Application pending·0 cites
- 1633US6251144B1Enzymatic compositions and methods for producing stonewashed look on indigo-dyed denim fabric and garmentsGENENCOR INT·Filed 1995·Granted Jun 26, 2001·5 cites·21 claims
Join the waitlist — get patent alerts
Get an alert when Curran Matthew Simpson files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →